Corporate | 30 April 2008 12:19
STRATEC Biomedical Systems AG / Quarter Results Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- STRATEC presents preliminary figures for the first quarter of 2008 Birkenfeld, April 30, 2008 The sales and earnings figures of the STRATEC Group for the first three months of the 2008 financial are within the range expected by the company. The preliminary unaudited consolidated figures of the STRATEC Group pursuant to IFRS (International Financial Reporting Standards) for the first quarter of the 2008 financial year ending on March 31, 2008 are as follows:Key Figures (EUR 000s) 01.01.- 03.31.2008 01.01.- 03.31.2007 Change Sales 13,208 15,674 -15.7% Gross performance 14,767 16,131 -8.5% EBITDA 2,691 3,055 -11.9% EBIT 2,110 2,505 -15.8% EBT 2,167 2,534 -14.5% Consolidated net income 1,661 1,930 -13.9% Earnings per share (EUR) 0.15 0.17 -11.8%Including temporary employees, the STRATEC Group had a total of 264 employees as of March 31, 2008 (previous year: 246). Even though turnover continues to rise in the regular STRATEC business and potential production figures are not yet able to cover customer demand in individual production lines, the side effects of an acquisition-related temporary weakness in acceptance volumes on the part of one of our most important customers has resulted in a consolidation of our sales and earnings. The sustainable forecast provided to us by this customer for the period October 2008 to September 2009 documents that this represents a merely temporary phenomenon. Based on this forecast, the acceptance volumes for the serial analyzer system in the aforementioned period will significantly exceed the number of serial analyzer systems accepted by this customer in the 2006 financial year. The long-term growth of our company is secured by a large number of development and supply agreements. In particular, the development status of existing development projects, as well as of projects currently in the process of being initiated, indicate a positive business performance. Hermann Leistner, Chairman of the Board of Management of STRATEC Biomedical Systems AG: 'Individual phases of consolidation, in this case due to the merging of business divisions at one of our customers, have only a temporary impact on the further positive performance of our company. The products currently in development are based on long-term agreements with our customers. They will be in the supply phase from 2009 until at least 2017. Together with the projects we are currently negotiating with major customers, these analyzer systems will secure STRATEC’s growth in the long term. With its wide range of future technologies STRATEC, as a market and innovation leader, is in a strong position to sustainably participate in the current and future outsourcing needs and the outstanding renewal investments of the diagnostics industry.' STRATEC's management continues to expect to generate sales of between Euro 78 million and Euro 82 million and earnings before taxes (EBIT) of Euro 16.2 million to Euro 18.2 million in the 2008 financial year. The extensive interim report will be available for downloading from our internet site from around 3 p.m. on May 15, 2008. About STRATEC STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and on other exchanges. The STRATEC Group consists of the publicly listed parent company STRATEC Biomedical Systems AG and of subsidiaries and second-tier subsidiaries in Germany, the USA, the UK, Switzerland and Romania. Further information can be obtained from: STRATEC Biomedical Systems AG André Loy, Investor Relations Gewerbestr. 37, 75217 Birkenfeld Germany Tel: +49 7082 7916 190 Fax: +49 7082 7916 999 E-mail: ir@stratec-biomedical.de 30.04.2008 Financial News transmitted by DGAP ---------------------------------------------------------------------- Language: English Issuer: STRATEC Biomedical Systems AG Gewerbestraße 37 75217 Birkenfeld Deutschland Phone: +49 (0)7082 7916 0 Fax: +49 (0)7082 7916 999 E-mail: info@stratec-biomedical.de Internet: www.stratec-biomedical.de ISIN: DE0007289001 WKN: 728900 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Stuttgart, München, Düsseldorf End of News DGAP News-Service ---------------------------------------------------------------------------